The National Institute for Health and Care Excellence (NICE) has recommended the use of olaparib (Lynparza) for BRCA-mutated early breast cancer and hormone-relapsed metastatic prostate cancer ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported statistically significant improvement in median PFS with the combination added to standard ...

Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olaparib and adavosertib, if they are given in sequence rather than ...

Please provide your email address to receive an email when new articles are posted on . Olaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with ...

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA-mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3-year ...

ASCO officials characterized the results as practice changing and said they highlighted the need for genetic testing in patients who receive a diagnosis of high-risk breast cancer. Giving olaparib to ...

SAN FRANCISCO -- Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median ...

A phase 3 trial evaluating olaparib (Lynparza) against standard of care chemotherapy in women with HER2-negative metastatic breast cancer has seen significant improvement in progression-free survival ...

The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting. The Food and Drug Administration (FDA) has accepted for Priority Review the ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

Adjuvant olaparib (Lynparza) significantly improves overall survival (OS), compared with placebo, for patients with high-risk, early-stage, HER2-negative, germline BRCA-mutated breast cancer, ...